|
US2007054872A1
|
|
Regulatable or conditional expression systems
|
|
US2007048254A1
|
|
Generation of dendritic cells
|
|
WO2006081074A2
|
|
Charge neutralization of polyion complexes
|
|
WO2006014588A2
|
|
Nucleic acid end-labeling reagents
|
|
WO2006009784A1
|
|
Small interfering rna with improved activity
|
|
US7098032B2
|
|
Compositions and methods for drug delivery using pH sensitive molecules
|
|
US7094605B2
|
|
Formation of polyampholytes in the presence of a polyion
|
|
US7015040B2
|
|
Intravascular delivery of nucleic acid
|
|
CA2530510A1
|
|
Improved delivery by labile hydrophobic modification of drugs
|
|
US7348453B2
|
|
Labile linkage for compound delivery to a cell
|
|
US7098030B2
|
|
Polyampholytes for delivering polyions to a cell
|
|
EP1646282A1
|
|
Genetic vaccines for cancer therapy
|
|
EP1594883A2
|
|
Covalent modification of rna for in vitro and in vivo delivery
|
|
US7435723B2
|
|
Process for delivery of polynucleotides to the prostate
|
|
EP1679964A2
|
|
Compostions and processes using sirna amphipathic compounds and polycations
|
|
US7148205B2
|
|
Intravascular delivery of non-viral nucleic acid
|
|
EP1507874A2
|
|
Compositions and processes for inhibiting gene expression using polynucleotides
|
|
US2005250683A9
|
|
Reversible modification of membrane interaction
|
|
US7214369B2
|
|
Devices and processes for distribution of genetic material to mammalian limb
|
|
EP1461052A2
|
|
Nucleic acid injected into hepatic vein lumen and delivered to primate liver
|
